drugset / Trial / NCT04022096
Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Esophagitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to confirm the non-inferiority of Tegoprazan 25mg, compared to Lansoprazole 15mg as maintenance therapy in patients with healed erosive esophagitis confirmed by endoscopy following oral administration once daily(QD) for 6 months.
Timeline
- Start
- 2019-06-18
- Primary completion
- 2021-06-23
- Completion
- 2021-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lansoprazole | Other / unclassified | 15 mg | Oral |
| Subject | Tegoprazan | Other / unclassified | 25 mg | — |